Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.

Cancer biology & therapy - 15 Apr 2011

Rohrberg Kristoffer Staal, Pappot Helle, Lassen Ulrik, Westman Maj, Olesen René K, Pfeiffer Per, Ladekarl Morten, Sørensen Morten, Christensen Ib J, Skov Birgit G

Abstract excerpt

Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analysed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab. The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gastrointestinal Neoplasms

Share to Quinazolines

Share to ras Proteins

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 21330783
DOI: 10.4161/cbt.11.8.14889

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.PMID 21330783Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.Semantic proximity Read ↗

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Semantic proximity Read ↗

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.Semantic proximity Read ↗

Circulating biomarkers of bevacizumab activity in patients with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.